Publications & Posters
Scholarly publications
Spinal Muscular Atrophy
Apitegromab
February 2026
Expert Review of Neurotherapeutics
Advancing treatment of spinal muscular atrophy through inhibition of the myostatin signaling pathway
Immuno-Oncology
Linavonkibart
January 2026
Linavonkibart publication
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial
Spinal Muscular Atrophy
Apitegromab
August 2025
The Lancet Neurology
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial
Spinal Muscular Atrophy
July 2025
Annals of Clinical and Translational Neurology
Remaining Burden of Spinal Muscular Atrophy Among Treated Patients: A Survey of Patients and Caregivers
Spinal Muscular Atrophy
Apitegromab
July 2024
Frontiers in Neurology
Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study
Fibrosis
SRK-373
July 2024
Science Signaling
